Pharma Mar, S.A. (BME:PHM)
Spain · Delayed Price · Currency is EUR 78.65
+0.95 (1.22%)
Aug 7, 2026, 2:29 PM CET
Pharma Mar Stock Forecast
Stock Price Forecast
According to 9 analysts polled by S&P Global, Pharma Mar stock has a consensus rating of "Buy" and an average price target of €104.39. The average 1-year stock price forecast is 32.73% higher than the current stock price, while the lowest is €85.50 (+8.71%) and the highest is €125.00 (+58.93%).
Price Target: €104.39 (+32.73%)
Analyst Consensus: Buy
Price Target
Chart* Price targets were last updated on Jun 15, 2026.
Analyst Ratings
The average analyst rating for Pharma Mar stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 6 | 6 | 6 | 6 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 9 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Buy Maintains €67.00 → €100.00 | Buy | Maintains | €67.00 → €100.00 | +27.15% | Jun 15, 2026 |
| BTIG | BTIG | Buy Initiates €121.00 | Buy | Initiates | €121.00 | +53.85% | Apr 23, 2026 |
Financial Forecast
Revenue This Year
217.95M
from 221.39M
Decreased by -1.55%
Revenue Next Year
299.53M
from 217.95M
Increased by 37.43%
EPS This Year
2.37
from 4.30
Decreased by -45.00%
EPS Next Year
6.18
from 2.37
Increased by 161.50%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is EUR.